Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in Asian patients with atrial fibrillation:time for a reappraisal by Lip, Gregory Y.h. et al.
 
 
Non-vitamin K antagonist oral anticoagulants
(NOACs) for stroke prevention in Asian patients
with atrial fibrillation
Lip, Gregory; Wang, Kang-ling; Chiang, Chern-en
DOI:
10.1016/j.ijcard.2014.11.182
License:
Other (please specify with Rights Statement)
Document Version
Peer reviewed version
Citation for published version (Harvard):
Lip, GYH, Wang, K & Chiang, C 2015, 'Non-vitamin K antagonist oral anticoagulants (NOACs) for stroke
prevention in Asian patients with atrial fibrillation: time for a reappraisal', International Journal of Cardiology, vol.
180, pp. 246-254. https://doi.org/10.1016/j.ijcard.2014.11.182
Link to publication on Research at Birmingham portal
Publisher Rights Statement:
NOTICE: this is the author’s version of a work that was accepted for publication. Changes resulting from the publishing process, such as
peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes
may have been made to this work since it was submitted for publication. A definitive version was subsequently published as Lip Gregory
Y.H., Wang Kang-Ling, Chiang Chern-En, Non-Vitamin K Oral Anticoagulants (NOACs) for stroke prevention in Asian patients with atrial
fibrillation: Time for a reappraisal, International Journal of Cardiology (2014), doi: 10.1016/j.ijcard.2014.11.182
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
  	

Non-Vitamin K Oral Anticoagulants (NOACs) for stroke prevention in Asian
patients with atrial fibrillation: Time for a reappraisal
Gregory Y.H. Lip, Kang-Ling Wang, Chern-En Chiang
PII: S0167-5273(14)02363-8
DOI: doi: 10.1016/j.ijcard.2014.11.182
Reference: IJCA 19339
To appear in: International Journal of Cardiology
Received date: 10 November 2014
Accepted date: 23 November 2014
Please cite this article as: Lip Gregory Y.H., Wang Kang-Ling, Chiang Chern-En, Non-
Vitamin K Oral Anticoagulants (NOACs) for stroke prevention in Asian patients with
atrial ﬁbrillation: Time for a reappraisal, International Journal of Cardiology (2014), doi:
10.1016/j.ijcard.2014.11.182
This is a PDF ﬁle of an unedited manuscript that has been accepted for publication.
As a service to our customers we are providing this early version of the manuscript.
The manuscript will undergo copyediting, typesetting, and review of the resulting proof
before it is published in its ﬁnal form. Please note that during the production process
errors may be discovered which could aﬀect the content, and all legal disclaimers that
apply to the journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
1 
 
Non-Vitamin K Oral Anticoagulants (NOACs) for stroke prevention in Asian patients 
with atrial fibrillation: Time for a reappraisal 
 
Gregory Y H Lip1,2, MD; Kang-Ling Wang3, MD; Chern-En Chiang3, MD, PhD 
 
1University of Birmingham Centre for Cardiovascular Sciences, City Hospital, 
Birmingham, United Kingdom; 
2 Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of 
Health, Aalborg University, Aalborg, Denmark; and 
3General Clinical Research Center and Division of Cardiology, Taipei Veterans General 
Hospital and National Yang-Ming University, Taipei, Taiwan; 
 
Address for correspondence: 
Professor Chern-En Chiang 
Division of Cardiology 
Taipei Veterans General Hospital 
201, Section 2, Shih-Pai Road 
Taipei 112, Taiwan 
Tel: +886228757774 
Fax: +886228745422 
E-mail: cechiang@vghtpe.gov.tw 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
2 
 
Or 
Professor Gregory Y H Lip 
Professor of Cardiovascular Medicine 
University of Birmingham,  
Centre for Cardiovascular Sciences 
City Hospital 
Birmingham B18 7QH 
England, UK 
Tel: +44 121 5075080 
Fax: +44 121 554 4083 
E-mail: g.y.h.lip@bham.ac.uk 
 
Running title: Stroke prevention in atrial fibrillation in Asia 
 
Word count: , 250 (abstract) 
References: 55; Table: 3; Figures: 8 
 
Author contribution: 
G.Y.H. Lip made main contributions in study conception, data interpretation and 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
3 
 
manuscript drafting/revisions. KL Wang made the primary contribution in data 
collection, figure drawing, and manuscript drafting/revisions. CE Chiang made the 
contribution to study conception, data interpretation and manuscript revisions. All 
authors contributed to interpretation of results, revising the manuscript critically for 
important intellectual content, and all approved the final manuscript. 
 
Study funding: This work was supported, in part, by grants from the Taiwan Ministry 
of Health and Welfare (MOHW103-TDU-B-211-113-003) and intramural grants from 
the Taipei Veterans General Hospital (V103B-024; V103C-051) 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
4 
 
 
Abstract 
Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) have changed the landscape 
for stroke prevention in atrial fibrillation (AF). Given the huge burden of AF in Asians, 
more attention to stroke prevention is clearly needed. Aiming to provide an overview 
and reappraisal of stroke prevention in Asians with AF, we searched MEDLINE for 
information on NOACs in Asians. In addition, abstracts from national and 
international cardiovascular meetings were studied to identify unpublished studies. 
In the 4 recent Phase 3 trials comparing NOACs to warfarin, a consistent pattern is 
evident. For efficacy endpoints in the comparison of NOACs vs warfarin, a significant 
reduction in stroke/systemic embolization was seen for dabigatran 150mg [HR 0.45 
(0.28-0.72)], with non-significant trends seen for lower stroke/systemic embolization 
with other NOACs, except edoxaban 30mg. A similar pattern was seen for ischaemic 
stroke, with a significant reduction for dabigatran 150mg [HR 0.55 (0.32-0.950]. For 
haemorrhagic stroke, all NOACs regimes, except rivaroxaban 20mg, had significantly 
lower hazard ratios. No evidence of increased myocardial infarction was found for 
NOACs. All-cause mortality was significantly lowered amongst Asian patients on 
edoxaban 60mg compared to warfarin [HR 0.63 (0.40-0.98)] with non-significant 
trends to lower mortality with dabigatran 150mg, rivaroxaban and edoxaban 30mg. 
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For safety endpoints, all the NOACs regimes, except rivaroxaban 20 mg, significantly 
reduced major bleeding and ‘all bleeding’ events. Intracranial haemorrhage was 
consistently lowered by all NOACs. None of NOACs increased gastrointestinal 
bleeding. These information suggested that NOACs should be preferentially indicated 
for stroke prevention in Asians with AF. 
 
Key words  anticoagulant, Asia, atrial fibrillation, stroke, thromboembolism  
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Introduction 
 
Atrial fibrillation (AF) is the commonest sustained cardiac arrhythmia, and represents 
a global problem [1]. Whilst the prevalence is broadly similar to epidemiological data 
from Western countries, given the size of the increasingly elderly Asian population 
(for example, in China), the absolute numbers of patients with AF in Asia are 
substantially higher than Europe or the United States [2].  Given the AF confers a 
substantial risk of mortality and morbidity from stroke, thromboembolism, heart 
failure, cognitive impairment and poor quality of life, the public health and 
healthcare burden associated with AF is huge.  
 
Stroke prevention is central to the management of AF, given the increased risk of 
stroke and thromboembolism associated with this arrhythmia.  Strokes associated 
with AF are associated with a higher mortality, greater disability, longer hospital stays 
and lower rates of discharge to one’s own home.   
 
Whilst it is well established that effective stroke prevention requires oral 
anticoagulation (OAC), the problem until recently was compounded by the 
substantial numbers of patients in Asia that are not treated with OACs (usually 
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Vitamin K Antagonists (VKAs, eg. warfarin), and even those managed with VKAs have 
poor quality anticoagulation control (as reflected by poor time in therapeutic range 
(TTR)) or not having access to a structured anticoagulation monitoring service [2, 3].  
High quality anticoagulation control (eg average individual TTRs >70%) has been 
associated with low rates of stroke and bleeding [4-6].  Thus, stroke rates whilst on 
warfarin therapy in some ‘real world’ Asian cohorts (where TTR is poor) are no 
different to those on aspirin or those untreated [7]. 
 
The availability of Non-VKA Oral Anticoagulants (NOACs, previously referred to as 
new or novel OACs [8] has changed the landscape for stroke prevention in AF.  
These drugs offer relative efficacy, safety and convenience compared to the VKAs.  
The NOACs fall into 2 categories – the oral direct thrombin inhibitors (eg. dabigatran) 
and the oral Factor Xa inhibitors (eg. rivaroxaban, apixaban and edoxaban) and have 
been compared to warfarin in large Phase 3 clinical trials.   These trials were 
conducted as global trials, and substantial numbers of patients from Asian countries 
were participants.   
 
The objective of this review is to provide an overview and reappraisal of stroke 
prevention in Asian patients with AF, with particular focus on the data on NOACs in 
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Asians. 
 
 
Search strategy 
 
We searched MEDLINE using the following terms individually and/or in combination:  
'Asians', ‘atrial fibrillation’, ‘stroke’, ‘thromboembolism ‘ ‘anticoagulation’, 
‘antiplatelet therapy’, ‘dabigatran’, ‘rivaroxaban’, ‘apixaban’, ‘edoxaban’, ‘direct 
thrombin inhibitors’, ‘Factor Xa inhibitors’, ‘NOACs’. In addition, abstracts from 
national and international cardiovascular meetings were studied to identify 
unpublished studies. The extensive detailed literature on the underlying 
pathophysiology of thromboembolism AF will not be addressed in this article, which 
particularly concentrates on the management aspects. 
  
 
Epidemiology – a brief overview 
Much of the epidemiology of AF comes from Western countries.  A recent 
systematic review of epidemiology of AF in regions outside North America and 
Europe found that the reported prevalence of AF varied among countries, with 
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different ranges in community- and hospital-based studies (0.1%-4% and 2.8%-14%, 
respectively) [1]. The use of anticoagulant therapy varied widely among countries 
and studies, as did the reported prevalence of stroke in patients with AF 
(2.8%-24.2%).   
Specific data on associated comorbidities from surveys and cohort studies of AF from 
various Asian countries, compared to non-Asians are summarized in Table 1 [3, 9-15].  
The average age and proportion of females in Asians and non-Asians was broadly 
similar.  As with Western countries, the most prevalent associated comorbidity was 
hypertension, with a trend towards a higher proportion with prior stroke/transient 
ischemic attach (TIA) amongst Asian patients.  Other comorbidities were broadly 
similar, although formal comparisons across the different studies are difficult given 
the differences in study design and setting.   
 
Table 2 summarises the main comorbidities from the Asian patients included in the 4 
large Phase 3 randomised trials [16-19].  In RE-LY, the prevalence of heart failure, 
hypertension, diabetes, and the mean CHADS2 (Congestive heart failure, 
Hypertension, Age≥75 [doubled], Diabetes, Stroke [doubled]) score were broadly 
similar between Asians and non-Asians.  There was a lower proportion of those age 
≥75 in Asians, with a higher proportion with prior stroke/TIA.  In ROCKET-AF, the 
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East Asian cohort had a lower prevalence of heart failure and hypertension, and 
again, had higher proportion with prior stroke/TIA.  In ARISTOTLE and ENGAGE-AF, 
Asians had lower prevalence of heart failure and higher proportion of prior 
stroke/TIA.  In ENGAGE-AF, the proportion with heart failure, hypertension tended 
to be lower, compared to non-Asians.   
 
The burden of AF-associated stroke is probably higher in Asians, but the value of OAC 
is maintained.  In a recent study amongst 2339 elderly (age ≥80) hospitalized 
Chinese patients from Hong Kong, elderly Asians had higher stroke rates after a 
2.2-year follow-up as high as 80.8% on no antithrombotic therapy [3, 20].  
 
Whilst the data from Hong Kong are generally reassuring, other considerations are 
necessary.  Proportionally the ratio between ischaemic stroke to haemorrhagic 
stroke is lower in Asians compared to non-Asians [21].  Also, Asian patients have a 
higher mortality due to warfarin-induced intra-cranial haemorrhage (ICH) (62%) 
compared to Caucasians [22]  Nonetheless, the higher risks associated with Asians, 
may not be a problem solely with warfarin.  In the Hong Kong series, for example, 
the annual incidence of ICH in patients taking aspirin and warfarin was 0.77% per 
year and 0.80% per year, respectively [3]. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
11 
 
 
Stroke risk assessment 
Whilst AF increases the risk of stroke five-fold, this risk is not homogeneous, and is 
dependent upon the presence of stroke risk factors.  Stroke risk stratification has 
been made using risk scores such as the CHADS2 score, which derived 5 common 
stroke risk factors from the non-VKA arms of the historical trial cohorts[23] [24].  
The latter trials have been criticized for randomizing <10% of patients screened, and 
many risk factors were not recorded nor consistently defined.  The CHADS2 score 
was used to categorise ‘high risk’ patients to be targeted for VKA therapy (but 
numerous studies still showed that high risk patients were undertreated).  Also, the 
predictive value of this score was modest (c-statistic approx. 0.6) and in recent Asian 
cohorts, the CHADS2 score did not significantly predict stroke [3, 7]. 
 
More recently, the CHA2DS2-VASc score [25] (Congestive heart failure, Hypertension, 
Age ≥75 [doubled], Diabetes, Stroke [doubled]-Vascular disease, Age 65–74, Sex 
category [female]) has been recommended for stroke risk assessment, by the latest 
major guidelines from the European Society of Cardiology (ESC), Asia-Pacific Heart 
Rhythm Society (APHRS), American Heart Association/American College of 
Cardiology/Heart Rhythm Society (AHA/ACC/HRS) and the National Institute for 
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Health and Care Excellence (NICE).  The CHA2DS2-VASc score is more inclusive of 
common stroke risk factors in AF, and performs best at initially identifying the ‘low 
risk’ AF patients (ie. CHA2DS2-VASc score =0 in males, score=1 in females) who do not 
need any antithrombotic therapy.  Subsequent to this initial step, stroke prevention 
can be offered to AF patients with ≥1 additional stroke risk factors ie. CHA2DS2-VASc 
score = 1 (males) or ≥2 (everyone).   
 
The CHA2DS2-VASc score has been validated in various Asian populations, including 
those from China, Hong Kong, Taiwan, South Korea and Japan.  Indeed, 
CHA2DS2-VASc (but not CHADS2) was a significant predictor of stroke/systemic 
embolization in Asian patients with AF [3, 7, 26], thus justifying its adoption in the 
major guidelines. 
 
Bleeding risk assessment 
Various risk scores for predicting bleeding in AF have been proposed, but until 
recently, uptake has been poor due to their complexity and (in some cases) the need 
to quality some parameters, such as ‘genetic factors’ [27]. 
 
More recently, the HAS-BLED (Hypertension, Abnormal renal/liver function, Stroke, 
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Bleeding history or predisposition, Labile INR, Elderly, Drugs/alcohol concomitantly) 
score has been proposed as a simple clinical score to predict clinically relevant 
bleeding in AF patients [28], and this score has now been well-validated to predict 
major bleeding and intracranial bleeding. HAS-BLED outperformed all other bleeding 
risk scores and has also been validated in VKA and non-VKA anticoagulated patients.  
Furthermore, HAS-BLED has been validated in Asian patients[7].  The HAS-BLED 
score has been recommended in the major guidelines from the ESC, Canadian 
Cardiovascular Society and NICE [29-31]. 
 
Nonetheless, the HAS-BLED score needs to be used appropriately, and a high score is 
not an excuse to withhold OAC but to ‘flag up’ patients potentially at risk for bleeding 
for more careful review and follow-up.  Also, HAS-BLED makes the clinician think 
about the correctable risk factors for bleeding, such as uncontrolled hypertension 
(the ‘H’ in HAS-BLED), labile INRs (L, only applies on a VKA patient), concomitant 
drugs such as aspirin or NSAIDs or alcohol excess/abuse (the D in HAS-BLED).  A risk 
of falls per se is not an independent predictor for OAC-related bleeding [32].   
 
 
Aspirin in Asian patients 
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What about antiplatelet therapy?  In the historical trials, aspirin had a small and 
non-significant 19% reduction in stroke, with no impact on mortality [33].  This 19% 
reduction was driven by the one single positive trial (SPAF-1) which had major 
internal heterogeneity for the aspirin effect against placebo/control, reducing stroke 
by 94% in anticoagulation-eligible patients and by only 8% in 
anticoagulation-ineligible patients.  The SPAF-1 trial used aspirin 325mg daily and 
had been stopped early hence possibly exaggerating the aspirin efficacy results.  
Also, aspirin did not reduce strokes in those age >75, nor did it prevent severe 
strokes.   
 
The data for the efficacy and safety of aspirin in Asian patients with AF are similarly 
weak. In the Chinese AF cohort study from Hong Kong, the stroke rate was 66.9% in 
patients on warfarin compared with 80.8% in patients with no antithrombotic 
therapy (hazard ratio, 0.53; 95%CI 0.48-0.58; P<0.001).  Aspirin had a 
non-significant 18.7% reduction in ischaemic strokes.  In contrast, warfarin-treated 
patients also had a better mortality rate (hazard ratio, 0.40; 0.37-0.45; P<0.0001) and 
ischemic stroke rate (hazard ratio, 0.64; 0.54-0.77; P<0.0001) [3, 20].  As mentioned 
above, the ICH rate in Chinese patients taking aspirin and warfarin was 0.77% per 
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year and 0.80% per year, respectively [3].  Analysis of the net clinical benefit favored 
the use of warfarin over aspirin or no therapy for stroke prevention in a broad range 
of Chinese AF patients.   
 
Even amongst low risk patients with AF, use of aspirin did not reduce 
thromboembolism, but had a tendency to more bleeding and intracranial bleeding 
[34]. 
 
Despite the (very) weak data for aspirin, as well as the poor efficacy and safety for 
aspirin in stroke prevention for AF, the use of aspirin is highly prevalent in many Asian 
countries (eg. China) [35] and its use continues to be recommended in some 
country-specific treatment guidelines, putting patients at risk of stroke and exposing 
them to aspirin-related bleeding. 
 
 
Anticoagulation in Asian patients 
 
Data on warfarin in Asians 
In the 4 recent Phase 3 trials comparing NOACs to warfarin, a consistent pattern is 
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evident.  There were generally higher rates of stroke/systemic embolism (the 
primary efficacy endpoint), ischaemic stroke and haemorrhagic stroke on warfarin in 
Asians vs non-Asians, despite similar or lower CHADS2 scores [Figure 1] [16-19].   
All-cause mortality was higher in Asians on warfarin, compared to non-Asians in RE-LY, 
but not in the other 3 trials.  Myocardial infarction events tended to be lower in 
Asian patients compared to non-Asians, in all the trials. 
 
For safety endpoints, rates of major bleeding, intracranial bleeding and ‘all bleeding’ 
were also higher in Asians compared to non-Asians [Figure 2] [16-19].  In RE-LY, the 
risk of gastrointestinal bleeding was also higher in Asians, but lower in ENGAGE-AF.    
 
The higher rates of serious bleeding may be related to the tendency to poorer TTRs 
in Asians [Figure 3], but other considerations, including the higher proportion of prior 
stroke/TIA amongst Asian subjects. [16-19],[36]  Poorer TTRs in Asians have been 
attributed to diet, herbal medicines, etc [37, 38]; however, the lack of structured 
anticoagulation services in many Asian countries may be an added logistic issue that 
precludes effective VKA management. 
 
Data on NOACs in Asians 
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Forest plots showing relative risk reductions in Asians vs Non-Asians for the efficacy 
endpoints of stroke+systemic embolic events, ischemic stroke, hemorrhagic stroke, 
MI and all-cause death, are shown in Figure 4 [16-19].  Notwithstanding the 
limitations of indirect comparisons, given the smaller size cohorts of the Asians, a 
significant reduction in stroke/SE was seen for dabigatran 150mg [HR 0.45 
(0.28-0.72)], with non-significant trends seen for lower stroke/SE with dabigatran 
110mg, rivaroxaban, apixaban and edoxaban 60mg.  
 
A similar pattern was seen for ischaemic stroke, with a significant reduction seen for 
dabigatran 150mg [HR 0.55 (0.32-0.950], with a trend towards higher rates seen for 
edoxaban 30mg.  For haemorrhagic stroke, all NOAC regimes had significantly lower 
hazard ratios, with a non-significant trend for rivaroxaban 20mg.  For myocardial 
infarction, the non-significant trend seen for a numerical excess seen for dabigatran 
(both doses) and edoxaban 30mg amongst non-Asians, was reversed amongst Asians.  
In ARISTOTLE, there was a non-significant trend towards more MIs with apixaban 
compared to warfarin [HR 1.17 (0.42-3.23)].  All-cause mortality was significantly 
lowered amongst Asian patients on edoxaban 60mg compared to warfarin [HR 0.63 
(0.40-0.98)] with non-significant trends to lower mortality with dabigatran 150mg, 
rivaroxaban and edoxaban 30mg.   
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Corresponding absolute risk reductions for efficacy endpoints are shown in Figure 5 
[16-19]. 
 
Similar forest plots for the safety endpoints of major bleeding, ICH, GI bleeding, and 
all bleeding are shown in Figure 6 [16-19].  Major bleeding was significantly lower 
amongst Asians on all the NOACs compared to warfarin, except for rivaroxaban 20mg.  
For ICH, all the NOACs had significantly lower rates compared to warfarin amongst 
Asians (and non-Asians).  For gastrointestinal bleeding, the higher bleeding rates in 
non-Asians seen with dabigatran 150mg and edoxaban 60mg when compared to 
warfarin were reversed, showing a non-significant trend towards being lower in 
Asians.  For the endpoint of ‘all bleeding’ in Asians this was significantly lowered 
with all NOACs, except for rivaroxaban, when compared to warfarin. 
 
Corresponding absolute risk reductions for safety endpoints are shown in Figure 7 
[16-19]. 
 
A summary table showing the efficacy and safety of NOACs in Asians (Table 3) clearly 
shows the main advantages of all the NOACs with lower haemorrhagic stroke and ICH, 
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compared to warfarin [16-19].  For major bleeding and ‘all bleeding’ this was 
significantly lower for all NOACs, with the exception of rivaroxaban.   
 
The net clinical benefit balancing stroke reduction against bleeding is generally in 
favour of anticoagulation in patients with ≥1 stroke risk factors [39], with the greater 
benefit seen for those at highest risk of stroke and bleeding.  In a modeling analysis, 
this was even more evident for the NOACs, compared to warfarin, in patients with a 
CHA2DS2-VASc score ≥1 [40] and this also applies to Asian patients [35]. 
 
However, net clinical benefit can be defined in different ways.  In RE-LY, the net 
clinical benefit outcome was the composite of stroke, systemic embolism, pulmonary 
embolism, myocardial infarction including silent myocardial infarction, death, or 
major bleeding, and this was consistently in favor of both doses of dabigatran 
compared with warfarin, in both Asians and non-Asians. Only the dabigatran 150 mg 
dose in Asians was clearly superior versus warfarin (HR, 0.66; 0.52–0.83) [16].  
 
Another consideration is the cost-effectiveness of these agents.  The NOACs are 
new drugs and thus, expensive when simply comparing drug costs against the older 
drug, warfarin.  The latter has additional costs in relation to INR monitoring, as well 
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as the various drug-related limitations (eg. diet, alcohol and drug restrictions) – in 
addition to the differences in efficacy and safety compared to NOACs.  Various 
cost-effectiveness analyses have been published related to different healthcare 
systems.  In the United Kingdom, for example, the NICE and SIGN (The Scottish 
Intercollegiate Guidelines Network) undertake cost-effectiveness analysis, and all 3 
licensed NOACs (dabigatran, rivaroxaban, apixaban) have been shown to be 
cost-effective options instead of warfarin.  Cost-effectiveness data from Asian 
countries are more limited, given the different healthcare systems.  In Taiwan, one 
analysis for dabigatran clearly shows the cost-effectiveness of this NOAC [41]. 
 
 
 
A practical approach 
 
Rather than focus on targeting ‘high risk’ patients for OAC use, a clinical practice shift 
is needed, so that the initial step is identification of the ‘truly low risk’ patients with 
AF.  These ‘truly low risk’ patients are those ‘age <65 and lone AF (both male and 
female)’, essentially a CHA2DS2-VASc score=0 (male) or 1 (female).  Subsequently, 
OAC can be offered to all other patients with ≥1 stroke risk factors. Ultimately 
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effective stroke prevention requires OAC use, whether delivered as a NOAC or as 
well-controlled VKA (TTR>70%).  Aspirin should not be used for stroke prevention in 
AF, given its inefficacy, poor safety and lack of cost effectiveness [31].   
 
Practical aspects of managing individual NOACs have addressed in numerous reviews 
[42-44].  Guideline or prescribing label-adherent use of dabigatran has been shown 
to result in better efficacy and safety outcomes.  Post-marketing ‘real world’ data 
for the NOACs have also confirmed the efficacy and safety of these agents [45, 46].   
 
Should all newly diagnosed patients with AF be started on a NOAC?  In some 
healthcare settings, a ‘warfarin stress test’ is mandated, to see if a satisfactory TTR 
can be achieved after 3-6 months.  Given that TTRs tend to be poor during the 
inception phase of introducing warfarin, such an approach may put patients at 
increased risk of stroke (>70% increased) [47].  A simple score based on clinical 
factors (SAMe-TT2R2) (Sex, Age [<60 years], Medical history, Treatment [interacting 
drugs eg amiodarone], Tobacco use [doubled], and Race (non-Caucasian) [doubled]) 
has recently been proposed to help identify upfront those patients less likely to do 
well on VKA (SAMe-TT2R2 score >2), where a NOAC or more intensive anticoagulation 
management can be applied [48].  The SAMe-TT2R2 score has been shown to be 
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predictive of poor TTRs and labile INRs, and as a consequence, a resultant increase in 
risk of thromboembolism, death and bleeding [49-51].  The SAMe-TT2R2 score 
requires validation (or calibration) in Asian populations. 
 
Irrespective of TTR, the benefits of NOACs on lowered haemorrhagic stroke and ICH 
compared to warfarin are maintained.  However, the impact on stroke/SE and major 
bleeding may be less evident at the high TTRs.  For example, in the case of either 
rivaroxaban or dabigatran, a reduction in one-year medical costs was no longer 
observed as warfarin’s TTR increased above 65% and 70 %, respectively [52].  
However, the use of apixaban was associated with a medical cost reduction across all 
warfarin TTR ranges evaluated (30–90%).  Given that average TTRs in many Asian 
countries are poor, NOACs would seem the best option unless substantial 
improvements in the quality of anticoagulation control are achieved. 
 
 
Conclusions 
 
Given the huge burden of AF and its complications related to stroke/SE in Asian 
countries, more attention to stroke prevention is clearly needed.  Patients place 
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more emphasis on stroke prevention than physicians.  In one recent study, patients 
were prepared to sustain 4 major bleeds, just to avoid one stroke which was viewed 
as a fate worse than death [53]. In contrast, physicians were more concerned with 
bleeding, at the cost of patients sustaining strokes [54].  Unless VKA management 
improves substantially, contemporary data from the warfarin arms of recent clinical 
trials shows how Asian patients do worse, with higher rates of thromboembolism 
and bleeding.  By contrast, the preferred OAC treatment option in Asians with AF 
for stroke prevention would be a NOAC. A suggested flow chart for the management 
of non-valvular AF is illustrated in Figure 8.  
 
A change in clinical approach, towards initially identifying ‘low risk’ patients using the 
CHA2DS2-VASc, then subsequently offering OAC to others with ≥1 stroke risk factors 
would have a major impact on reducing strokes and death on a population-wide 
basis [7, 55].  The HAS-BLED score can be used to flag up patients potentially at risk 
of bleeding, and to address the potentially correctable risk factors.   Risk 
assessment is a continuous and dynamic process, and appropriate application of 
guidelines would result in better outcomes for our patients, reducing the major 
burden of AF-related stroke in Asia.   
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Figure legends: 
 
Figure 1. Major cardiovascular events on warfarin in Asians vs non-Asians, from the 
randomised trials. A. Stroke and systemic embolization events; B. Ischaemic stroke; C. 
Haemorrhagic stroke; D. Myocardial infarction; E. All-cause death.  
 
Figure 2. Bleeding events on warfarin in Asians vs non-Asians, from the randomised 
trials. A. Major bleeding; B. Intra-cranial haemorrhage; C. Gastrointestinal bleeding; 
D. All (major plus minor) bleeding episodes.  
 
Figure 3. International normalized ratios (INRs) in the randomised trials. Asians in 
RE-LY included patients from China, Japan, South Korea, Taiwan, Hong Kong, 
Philippines, Singapore, Malaysia, Thailand, and India[16]. Asians in ROCKET included 
patients from China, South Korea, Taiwan, Hong Kong, Philippines, Singapore, 
Malaysia, and Thailand[36]. Asians in ARISTOTLE included patients from China, Japan, 
South Korea, Taiwan, Hong Kong, Philippines, Singapore, and Malaysia[18]. East 
Asians in ENGAGE included patients from China, Japan, South Korea, and Taiwan[19]. 
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Figure 4. Forest plots for efficacy endpoints with NOACs vs warfarin in Asians vs 
non-Asians, from the randomised trials. A. Stroke and systemic embolization events; 
B. Ischaemic stroke; C. Haemorrhagic stroke; D. Myocardial infarction; E. All-cause 
death. Lines of confidence interval and points of estimation were shown in red color 
for Asians and black color for non-Asians. NOACs = non-vitamin K antagonist oral 
anticoagulants 
 
Figure 5. Absolute risk reductions in efficacy endpoints with NOACs vs warfarin in 
Asians vs non-Asians, from the randomised trials. In general, the absolute risk 
reductions were numerically greater in Asians than in non-Asians. A. Stroke and 
systemic embolization events; B. Ischaemic stroke; C. Haemorrhagic stroke; D. 
Myocardial infarction; E. All-cause death. 
 
Figure 6. Forest plots for safety endpoints with NOACs vs warfarin in Asians vs 
non-Asians, from the randomised trials. A. Major bleeding; B. Intra-cranial 
haemorrhage; C. Gastrointestinal bleeding; D. All (major plus minor) bleeding 
episodes. Lines of confidence interval and points of estimation were shown in red 
color for Asians and black color for non-Asians. NOACs = non-vitamin K antagonist 
oral anticoagulants 
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Figure 7. Absolute risk reductions in safety endpoints with NOACs vs warfarin in 
Asians vs non-Asians, from the randomised trials. In general, the absolute risk 
reductions were numerically greater in Asians than in non-Asians. A. Major bleeding; 
B. Intra-cranial haemorrhage; C. Gastrointestinal bleeding; D. All (major plus minor) 
bleeding episodes. 
 
Figure 8. Flow chart for the management of non-valvular AF in Asians. AF = atrial 
fibrillation; CHA2DS2-VASc = Congestive heart failure, Hypertension, Age ≥75 
[doubled], Diabetes, Stroke [doubled]-Vascular disease, Age 65–74, Sex category 
[female]; NOACs = non-vitamin K antagonist oral anticoagulants 
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Table 1. Co-morbidities of AF in Asians vs non-Asians in survey and cohorts 
 Asians Non-Asians 
 J-Rhythm[9] HK[3] RECORDAF 
AP[10] 
REALISEAF 
Asia[11] 
RELY AF 
SouthEast 
Asia[12] 
ORBIT 
AF[13] 
Euro 
Heart 
Survey[14] 
RECORDAF[15] REALISEAF 
Europe[11] 
RELY AF 
West 
Europe[12] 
CHF (%) 34.4 22.8 25 35.7 26.3 32 33 26 33.2 21.2 
Hypertension 
(%) 
71.1 54.7 58 67.5 64.1 83 63 68 78.1 59.9 
Age (mean) 
(%) 
69.7 76.9 64 66.4 69.5 75 66 66 68.1 69.4 
Diabetes (%) 22.1 22.0 18 24.9 29.2 29 18 16 20.2 17.1 
Stroke/TIA 
(%) 
17.3 23.1 13 21.9 22.1 16 9 10 13.5 12.0 
CHD (%) 11.6 18.2 19 32.8 10.9* 32 32 18 36.4 18.2* 
Female (%) 31.1 52.1 40 45.9 44.6 42 43 43 40.4 38.8 
CHD: coronary heart disease; CHF: congestive heart failure; TIA: transient ischemic attack 
*: prior myocardial infarction  
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Table 2. Co-morbidities of AF in Asians vs non-Asians in clinical trials 
 Heart failure 
(%) 
Hypertension 
(%) 
Age75 
(%) 
Diabetes 
(%) 
Stroke/TIA 
(%) 
Mean CHADS2 
score  
RE-LY[16] 
Asians (n=2,782)* 
Non-Asians (n=15,331) 
 
36.3 
31.2 
 
71.2 
80.2 
 
27.4 
42.2 
 
25.1 
23.0 
 
24.2 
10.4 
 
2.2 
2.1 
ROCKET[17] 
East Asians (n=932)† 
Non-East Asians (n=13,322) 
 
38.6 
64.1 
 
79.9 
91.3 
(mean age) 
69.7 
71.3 
 
36.9 
40.1 
 
65.0 
54.0 
 
3.2 
3.5 
ARISTOTLE[18] 
Asians (n=1,993)‡ 
Non-Asians (n=16,202) 
 
26.2 
36.6 
 
82.3 
88.1 
 
24.4 
32.0 
 
25.2 
25.0 
 
28.8 
18.3 
 
2.1 
2.1 
ENGAGE[19] 
East Asians (n=1,943)§ 
Non-East Asians (n=19,162) 
 
47.3 
58.5 
 
82.1 
94.8 
 
37.5 
40.4 
 
35.0 
36.2 
 
42.4 
26.9 
 
2.9 
2.8 
TIA: transient ischemic attack 
*: China, Japan, South Korea, Taiwan, Hong Kong, Philippines, Singapore, Malaysia, Thailand, India 
†: China, South Korea, Taiwan, Hong Kong 
‡: China, Japan, South Korea, Taiwan, Hong Kong, Philippines, Singapore, Malaysia 
§: China, Japan, South Korea, Taiwan 
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Table 3. Efficacy and safety endpoints of different NOACs in Asians 
 Stroke/SEE Ischemic 
stroke 
Hemorrhagic 
stroke 
Myocardial 
infarction 
All-cause 
death 
Major 
bleeding 
Intra-cranial 
hemorrhage 
GI 
bleeding 
All 
bleeding 
Dabigatran* 
150 mg 
V V V   V V  V 
Dabigatran* 
110 mg 
  V   V V  V 
Rivaroxaban†       V   
Apixaban‡   V   V V  V 
Edoxaban§ 
60 mg 
  V  V V V  V 
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Edoxaban§  
30 mg 
  V   V V  V 
GI: gastrointestinal; SEE: systemic embolization events 
*: China, Japan, South Korea, Taiwan, Hong Kong, Philippines, Singapore, Malaysia, Thailand, India. 
†: China, South Korea, Taiwan, Hong Kong 
‡: China, Japan, South Korea, Taiwan, Hong Kong, Philippines, Singapore, Malaysia 
§: China, Japan, South Korea, Taiwan 
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Fig. 1 
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Fig. 2 
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Fig. 3 
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Fig. 4 
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Fig. 5 
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Fig. 6 
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Fig. 7 
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Fig. 8 
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Highlights 
 
 Data for Asians vs non-Asians were systemically reviewed in 4 megatrials of 
NOACs. 
 Warfarin induced more major bleeding and intracranial hemorrhage in Asians. 
 Bleeding events were generally lower for NOACs than Warfarin in Asians.  
 NOACs were superior or non-inferior to warfarin in stroke prevention in Asians. 
 NOACs should be preferentially indicated for stroke prevention in Asians with 
AF. 
